Books edited

  Systems Biology of Tumor Dormancy 
  Springer, 2013
  edited by Heiko Enderling, Nava Almog, and Lynn Hlatky
  Publisher Website


Special journal issues edited

  Computational Models in Oncology: from Tumor Initiation to Progression to Treatment
  Special Topic in Frontiers in Molecular and Cellular Oncology, 2013
  edited by K.A. Rejniak and H. Enderling
  [Open Access]

  Latest Developments in Mathematical Oncology and Cancer Systems Biology 
  Special Issue in Journal of Clinical Medicine, 2020
  edited by M.K. Jolly and H. Enderling
  [Open Access]

  Frontiers in Quantitative Cancer Modeling 
  Special Issue in Computational and Systems Oncology, 2021
  edited by M.K. Jolly and H. Enderling
  [Open Access]

  Challenges in Synergizing Radiation and Immunotherapy  
  Special Issue in Neoplasia, 2021
  edited by H. Enderling, U. Gaipl, M. Hecht
  [Open Access]


Journal articles


109. Predicting radiotherapy patient outcomes with real-time clinical data using mathematical modelling
AP Browning, TD Lewin, RE Baker, PK Maini, ED Moros, JJ Caudell, HM Byrne, H Enderling. Submitted, 2023. [Preprint]

108. Feasibility of an evolutionary tumor board for generating novel personalized therapeutic strategies
M Robertson-Tessi, JS Brown, MI Poole, M Johnson, A Marusyk, JA Gallaher, KA Luddy, CJ Whelan, J West, M Strobl, V Turati, H Enderling, MJ Schell, AC Tan, T Boyle, R Makanji, J Farinhas, H Soliman, D Lemanne, RA Gatenby, DR Reed, ARA Anderson, CH Chung. Submitted, 2023. [Preprint]

107. Mathematical models of tumor volume dynamics in response to radiotherapy
N Mohsin, H Enderling, R Brady-Nicholls, MU Zahid. Submitted, 2023. [Preprint]

106. Modelling radiation cancer treatment with a death-rate term in ordinary and fractional differential equations
N Wilson, CS Drapaca, H Enderling, JJ Caudell, KP Wilkie. Bull Math Biol, 85:47, 2023. [OpenAccess]

105. Predicting patient-specific tumor dynamics: How many measurements are necessary?
I Harshe, H Enderling, R Brady-Nicholls. Cancers, 15(5):1368, 2023. [Abstract] [OpenAccess]



104. Reimagining cancer staging in the era of evolutionary oncology
K Kirtane, MU Zahid, H Enderling, LB Harrison. J. Natl. Compr. Canc. Netw., 20(12):1370-1372, 2022. [abstract] [OpenAccess]

103. The tumor invasion paradox in cancer stem cell-driven solid tumors
A Shyntar, A Patel, M Rhodes, H Enderling, T Hillen. Bull. Math. Biol., 84:139, 2022. [abstract] [OpenAccess]

102. Range-bounded adaptive therapy to further leverage competition to improve adaptive therapy in metastatic prostate cancer
R Brady-Nicholls, H Enderling. Cancers, 14(21), 5319, 2022. [abstract] [OpenAccess]

101. Rethinking the immunotherapy numbers game
RA Bekker, MU Zahid, JM Binning, BQ Spring, P Hwu, S Pilon-Thomas, H Enderling. J. ImmunoTher. Cancer, 10(7):e005107, 2022. [abstract] [OpenAccess]

100. Mathematical modeling of radiotherapy and its impact on tumor interactions with the immune system
RA Bekker, S Kim, S Pilon-Thomas, H Enderling. Neoplasia, 28:100796, 2022. [abstract] [Open Access]

99. The radiosensitivity index (RSI) gene signature identifies distinct tumor immune microenvironment characteristics associated with susceptibility to radiotherapy
GD Grass, JC Lopez Alfonso, E Welsh, KA Ahmed, JK Teer, S Pilon-Thomas, LB Harrison, JL Cleveland, JJ Mule, SA Eschrich, H Enderling, JF Torres-Roca. Int. J. Radiat. Oncol. Biol. Phys., S0360-3016(22)00239-5, 2022. [abstract] [publisher]

98. Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab
DJ Glazar, M Johnson, J Farinhas, CE Steuer, NF Saba, M Bonomi, CH Chung, H EnderlingOral Oncol., 127:105787, 2022. [abstract] [Open Access]

97. Classical mathematical models for prediction of response to chemotherapy and immunotherapy
NG Laleh, CM Lavinia Loeffler, J Grajek, K Staňková, AT Pearson, HS Muti, C Trautwein, H Enderling, J Poleszczuk, JN KatherPLoS Comp. Biol., 18(2):e1009822, 2022. [abstract] [Open Access]

96. Predictive radiation oncology - A new NCI-DOE scientific space and community
Buchsbaum JC, Jaffray DA, Ba D, Borkon LL, Chalk C, Chung C, Coleman MA, Coleman CN, Diehn M, Droegemeier KK, Enderling H, Espey MG, Greenspan EJ, Hartshorn CM, Hoang T, Hsiao HT, Keppel C, Moore NW, Prior F, Stahlberg EA, Tourassi G, Willcox KERadiat. Res., 197(4):434-445, 2022. [abstract] [publisher]



95. Mathematical oncology: a new frontier in cancer biology and clinical decision making
H EnderlingPhys. Life Rev., S1571-0645(21)00076-2, 2021. [abstract] [publisher]

94. Dynamics-adapted radiotherapy dose (DARD) for head and neck cancer radiotherapy dose personalization 
MU Zahid, ASR Mohamed, JJ Caudell, LB Harrison, CD Fuller, EG Moros, H EnderlingJ. Pers. Med., 11(11), 1124, 2021. [abstract] [Open Access]

93. Intermittent hormone therapy models analysis and Bayesian-model-comparison for prostate cancer
S Pasetto, H Enderling, R Gatenby, R Brady-NichollsBull. Math. Biol., 84(1):2, 2021. [abstract] [Open Access]

92. Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: A modelling study based on longitudinal tumor measurements
SC Brueningk, J Peacock, CJ Whelan, R Brady-Nicholls, H-HM Yu, S Sahebjam, H EnderlingSci. Rep., 11(1):20219, 2021. [abstract] [Open Access]

91. Tumor-immune ecosystem dynamics define an individual Radiation Immune Score to predict pan-cancer radiocurability
JC Lopez Alfonso, GD Grass, E Welsh, KA Ahmed, JK Teer, S Pilon-Thomas, LB Harrison, JL Cleveland, JJ Mule, SA Eschrich, JF Torres-Roca, H Enderling. Neoplasia, 23(11):1110-1122, 2021. [abstract] [Open Access]

90. Predicting patient-specific response to adaptive therapy in metastatic castration resistant prostate cancer using prostate-specific antigen dynamics
R Brady-Nicholls, J Zhang, T Zhang, AZ Wang, R Butler, RA Gatenby, H Enderling. Neoplasia, 23(9):851-858, 2021. [abstract] [Open Access]

89. The evolutionary ecology of dormancy in nature and in cancer
AK Miller, JS Brown, H Enderling, D Basanta, CJ Whelan. Front. Ecol. Evol., 9:676802, 2021. [Open Access]

88. Forecasting individual patient response to radiotherapy in head and neck cancer with a dynamic carrying capacity model
MU Zahid, N Mohsin, ASR Mohamed, JJ Caudell, LB Harrison, CD Fuller, EG Moros, H EnderlingInt. J. Radiat. Oncol., Biol., Phys. S0360-3016(21)00676-3, 2021. [abstract ][Open Access]

87. A time-resolved experimental-mathematical model for predicting the response of glioma cells to single-dose radiation therapy
J Liu, DA Hormuth II, Tessa Davis, J Yang, MT McKenna, AM Jarrett, H Enderling, A Brock, TE YankeelovIntegr. Biol., 13(7):167-183, 2021. [abstract] [publisher]

86. Proliferation saturation index to characterize response to radiotherapy and evaluate altered fractionation in head and neck cancer
MU Zahid, ASR Mohamed, K Latifi, A Rishi, LB Harrison, CD Fuller, EG Moros, JJ Caudell, H Enderling. Appl. Rad. Oncol.18(1):18-25, 2021. [Open Access]

85. Bayesian framework to augment tumor board decision making
S Pasetto, RA Gatenby, H Enderling. JCO Clin. Cancer Inform. 5:508-517, 2021. [abstract] [Open Access]

84. Are all models wrong?
H Enderling, O Wolkenhauer. Comp. Sys. Oncol. 1:e1008., 2021. [abstract] [Open Access]

83. Education and outreach in physical sciences in oncology
SA Walker, A Pham, S Nizzero, M Kim, B Riter, J Bletz, S Judge, B Phillips, D Noble, D Murray, E Wetzel, S Samson, M McMahon, C Fink, J Couch, C Tomlin, K Swanson, ARA Anderson, D Odde, H Shen, S Hughes, N Zahir, H Enderling, J Wolfram. Trends Cancer 7(1): 3-9, 2021. [abstract] [publisher]

82. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high grade gliomas: results from a phase 1 study
S Sahebjam, PA Forsyth, ND Tran, J Arrington, R Macaulay, AB Etame, C Walko, T Boyle, EN Peguero, M Jaglal, S Mokhtari, H Enderling, N Raghunand, T Gatewookd, W Long, B Evernden, S Kim, ZJ Thompson, T Robinson, DT Chen, P Chinnaiyan, HHM Yu. Neuro Oncol. 23(4):677-686, 2021. [abstract] [publisher]



81. Heterogeneity analysis of MRI T2 maps for measurement of early tumor response to radiotherapy 
MR Tomaszewski, W Dominguez-Viqueira, A Ortiz, Y Shi, JR Costello, H Enderling, SA Rosenberg, RJ Gillies. NMR Biomed. 34(3):e4454, 2020. [abstract] [preprint

80. Tumor volume dynamics as an early biomarker for patient-specific evolution of resistance and progression in recurrent high-grade glioma
D Glazar, D Grass, J Arrington, P Forsyth, N Raghunand, H-HM Yu, S Sahebjam, H Enderling. J. Clin. Med. 9:2019, 2020.  [abstract[Open Access]

79. High school Internship Program in Integrated Mathematical Oncology (HIP IMO) – five-year experience at Moffitt Cancer Center
H Enderling, PM Altrock, N Andor, D Basanta, JS Brown, RA Gatenby, A Marusyk, KA  Rejniak, A Silva, ARA Anderson. Bull. Math. Biol. 82(7):91, 2020. [abstract] [preprint]

78. Re: Numerical simulation of normal and cancer cells’ populations with fractional derivative under radiotherapy
H Enderling. Comput. Meth. Prog. Bio. 188:105417, 2020. [abstract] [publisher]

77. Mathematical oncology and it’s application in non melanoma skin cancer–A primer for radiation oncology professionals
NJ Aherne, A Dhawan, JG Scott, H Enderling. Oral Oncol. 103:104473, 2020.  [abstract] [publisher]

76. Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation
R Brady, JD Nagy, TA Gerke, T Zhang, AZ Wang, J Zhang, RA Gatenby, H Enderling. Nat. Commun. 11:1750, 2020. [abstract[Open Access]

75. Mathematical modeling of oncolytic virotherapy
JPW Heidbuechel, D Abate-Daga, CE Engeland, H Enderling. Methods Mol. Biol. 2058:307-320, 2020. [abstract[publisher]   

74. Parameter estimation using aggregate data
HT Banks, AE Meade, C Schacht, J Catenacci, WC Thompson, D Abate Daga, H Enderling. Appl. Math. Lett. 100:105999, 2020. [publisher]

73. The importance of dead material within a tumour on the dynamics in response to radiotherapy
T Lewin, H Byrne, P Maini, J Caudell, E Moros, H Enderling. Phys. Med. Biol. 65(1):015007, 2020. [abstract[publisher]

72. A three phase model to investigate the effects of dead material on the growth of avascular tumours
TD Lewin, PK Maini, EG Moros, H Enderling, HM Byrne. Math. Model. Nat. Phenom. 15:22, 2020. [publisher]



71. Estimation of probability distributions of parameters using aggregate population data: Analysis of a CAR T-cell cancer model
C Schacht, AE Meade, HT Banks, H Enderling, D Abate Daga. Math. Biosci. Eng. 16(6):7299-7326, 2019. [abstract[Open Access]

70. Mathematical models of cancer – when to predict novel therapies, and when not to
R Brady, H Enderling. Bull. Math. Biol. 81(10):3722-3731, 2019. [abstract] [Open Access]

69. Integrating mathematical modeling into the roadmap for personalized adaptive radiation therapy
H Enderling, JCL Alfonso, E Moros, JJ Caudell, LB Harrison. Trends Cancer 5(8):467-474, 2019. [abstract[publisher]

68. The 2019 Mathematical oncology roadmap
R Rockne, A Hawkins-Daarud, K Swanson, J Sluka, J Glazier, P Macklin, D Hormuth, A Jarrett, E Lima, J Oden, G Biros, T Yahnkeelov, K Curtius, I Bakir, D Wodarz, N Komarova, L Aparicio, M Bordyuh, R Rabadan, S Finley, H Enderling, J Caudell, E Moros, A Anderson, R Gatenby, A Kaznatcheev, P Jeavons, N Krishnan, J Pelesko, R Wadhwa, N Yoon, D Nichol, A Marusyk, M Hinczewski, J Scott. Phys. Biol. 16(4):041005, 2019. [abstract] [Open Access]

67. Re: Simulation analysis for tumor radiotherapy based on three-component mathematical models
MC Ferrall-Fairbanks, D Glazar, R Brady, GJ Kimmel, MU Zahid, P Altrock, H Enderling. J. Appl. Clin. Med. Phys. 20(7):204-205, 2019. [abstract] [Open Access]

66. Illuminating the numbers: Integrating mathematical models to optimize photomedicine dosimetry and combination therapies
BQ Spring, RT Lang, EM Kercher, I Rizvi, RM Wenham, JR Conejo-Garcia, T Hasan, RA Gatenby, H Enderling. Front. Phys. 7:46, 2019. [abstract] [Open Access]

65. Proliferation Saturation Index in an adaptive Bayesian approach to predict patient-specific radiotherapy responses
ED Sunassee, D Tan, T Ji, R Brady, EG Moros, JJ Caudell, S Yartsev, H Enderling. Int. J. Rad. Biol. 4:1-6, 2019. [abstract[Preprint]

64. Immunologic consequences of sequencing cancer radiotherapy and surgery
JC Lopez Alfonso, J Poleszczuk, R Walker, S Kim, S Pilon-Thomas, JJ Conejo-Garcia, H Soliman, B Czerniecki, LB Harrison, H Enderling. JCO Clin. Cancer Inform. 3:1-16, 2019. [abstract

63. Personalizing gastric cancer screening with predictive modeling of disease progression biomarkers
R Walker, J Mejia, JK Lee, JM Pimiento, M Malafa, AR Giuliano, D Coppola, H EnderlingAppl. Immunohistochem. Mol. Morphol. 27(4):270-277, 2019. [abstract



62. The optimal radiation dose to induce robust systemic anti-tumor immunity
J Poleszczuk, H Enderling. Int J Mol Sci., 19(11), 2018. [abstract[Open Access]

61. The accelerating quest for optimal radiation and immunotherapy combinations for local and systemic tumor control
H Enderling, S Kim, S Pilon-Thomas. Ther. Radiol. Oncol. 2:33, 2018. [publisher] 

60. CD133 expression as a helicobacter pylori-independent biomarker of gastric cancer progression
R Howard, S Al Diffalha, J Pimiento, M Mejia, H Enderling, A Giuliano, D Coppola. Anticancer Res. 38(8):4443-4448, 2018. [abstract]

59. Immune interconnectivity of anatomically distant tumors potentiates systemic responses to local therapy
R Walker, J Poleszczuk, S Pilon-Thomas, S Kim, ARA Anderson, BJ Czerniecki, LB Harrison, EG Moros, H Enderling. Sci. Rep. 8(1):9474, 2018. [abstract[Open Access]

58. Temporally-feathered intensity modulated radiation therapy: A technique to reduce normal tissue toxicity
JCL Alfonso, S Parsai, N Joshi, A Godley, SA Koyfman, JJ Caudell, CD Fuller, H Enderling, JG Scott. Med. Phys. 45(7):3466-3474, 2018. [abstract[Preprint]

57. Report from the SWOG radiation oncology committee: Research Objectives Workshop 2017
P Okunieff, K Casey-Sawicki, NA Lockney, BS Hoppe, H Enderling, CC Pinnix, JW Welsh, S Krishnan, G Yothers, JM Brown, SJ Knox, RG Bristow, PT Spellman, T Miti, N Nabavizadeh, J Jaboi, HC Manning, FY Feng, SM Galbraith, AA Solanki, MM Harkenrider, R Tuli, RH Decker, SE Finkelstein, CC Hsu, CS Ha, R Jagsi, D Shumway, M Daly, TJC Wang, TJ FitzGerald, F Laurie, DT Marshall, D Raben, LS Constine, CR Thomas, LA Kachnic. Clin. Cancer Res., 24(15):3500-3509, 2018. [abstract]

56. The evolution of tumour composition during fractionated radiotherapy: implications for outcome
T Lewin, PK Maini, EG Moros, H Enderling, HM Byrne. Bull. Math. Biol., 80(5): 1207-1235, 2018. [abstract[Preprint]

55. Mathematical modeling of the effects of tumor heterogeneity on the efficiency of radiation treatment schedule
F Forouzannia, H Enderling, M Kohandel. Bull. Math. Biol., 80(2): 283-293, 2018. [abstract]

54. Toward early detection of Helicobacter pylori-associated gastric cancer
R Walker, J Poleszczuk, J Mejia, JK Lee, JM Pimiento, M Malafa, AR Giuliano, H Enderling, D Coppola. Gastric Cancer, 21(2): 196-203, 2018. [abstract]



53. Fighting cancer with mathematics and viruses
DN Santiago, JPW Heidbuechel, WM Kandell, R Walker, J Djeu, CE Engeland, D Abate-Daga, H Enderling. Viruses, 9(9): 239, 2017. [abstract[Open Access] 

52. Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival
J Poleszczuk, K Luddy, L Chen, J Lee, LB Harrison, BJ Czerniecki, H Soliman, H Enderling. Breast Cancer Res., 19:75, 2017. [abstract[Open Access[Press release]

51. Different sequences of fractionated low-dose proton and single iron-radiation-induced divergent biological responses in the heart
SP Sasi, X Yan, M Zuriaga-Herrero, H Gee, J Lee, R Mehrzad, J Song, J Onufrak, J Morgan, H Enderling, K Walsh, R Kishore, DA Goukassian. Radiat. Res., 188(2): 191-203, 2017. [abstract]

50. Evaluating the potential for maximized T cell redistribution entropy to improve abscopal responses to radiotherapy
R Walker, J Schoenfeld, S Pilon-Thomas, J Poleszczuk, H Enderling. Converg. Sci. Phys. Oncol., 3:034001, 2017. [Journal] [MedicalPhysicsWeb coverage]

49. Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx
JC Shiao, ASR Mohamed, JA Messer, KA Hutcheson, JM Johnson, H Enderling, M Kamal, BW Warren, B Pham, WH Morrison, ME Zafereo, AC Hessel, SY Lai, MS Kies, R Ferrarotto, AS Garden, DF Schomer, GB Gunn, J Phan, SJ Frank, BM Beadle, RS Weber, JS Lewin, DI Rosenthal, CD Fuller. Head Neck, 39(8): 1609-1620, 2017. [abstract

48. The future of personalised radiotherapy for head and neck cancer
JJ Caudell, JF Torres-Roca, RG Gillies, H Enderling, S Kim, A Rishi, EG Moros, LB Harrison. Lancet Oncol., 18(5): e266-273, 2017. [abstract[Journal]

47. Predicting patient-specific radiotherapy protocols based on mathematical model choice for Proliferation Saturation Index
J Poleszczuk, R Walker, EG Moros, K Latifi, JJ Caudell, H Enderling. Bull. Math. Biol., doi:10.1007/s11538-017-0279-0, 2017. [abstract]

46. Modeling T cell trafficking to increase the likelihood of radiation-induced abscopal effects
J Poleszczuk, E Moros, M Fishman, R Walker, J Djeu, J Schoenfeld, S Finkelstein, H Enderling. Journal of Targeted Therapies in Cancer, 06.17, 36-40, 2017. [Open Access]



45. CT-based volumetric tumor growth velocity: A novel imaging prognostic indicator in oropharyngeal cancer patients receiving radiotherapy
S Perni, AS Mohamed, J Scott, H Enderling, AS Garden, GB Gunn, DI Rosenthal, CD Fuller. Oral Oncol., 63: 16-22, 2016. [abstract]

44. Stratifying prostate cancer patients by relative lymph node involvement: population- and modeling-based study
J Poleszczuk, PA Johnstone, H Enderling. Cancer Med., 5(8): 1850-1855, 2016. [abstract] [Open Access]

43. Agent-based modeling of cancer stem cell driven solid tumor growth
J Poleszczuk, P Macklin, H Enderling. Methods Mol. Biol., 1516: 335-346, 2016. [abstract] [Preprint]

42. Abscopal benefits of localized radiotherapy depend on activated T cell trafficking and distribution within individual metastatic lesions
J Poleszczuk, KA Luddy, SA Prokopiou, M Robertson-Tessi, EG Moros, M Fishman, JY Djeu, SE Finkelstein, H Enderling. Cancer Res., 76(5); 1009-18, 2016. [abstract] [Open Access] [Commentary by Demaria & Formenti]

41. Cancer stem cell plasticity as tumor growth promoter and catalyst of population collapse
J Poleszczuk, H Enderling. Stem Cells Int., 2016:3923527, 2016. [abstract] [Open Access]

40. From concept to clinic: mathematically informed immunotherapy
R Walker, H Enderling. Curr. Probl. Cancer, 40(1): 68-83, 2016. [abstract] [pdf][Preprint]



39. A proliferation saturation index to predict radiation response and personalize radiotherapy fractionation
SA Prokopiou, EG Moros, J Poleszczuk, J Caudell, JF Torres-Roca, K Latifi, R Myerson, LB Harrison, H Enderling. Radiat. Oncol., 10:159, 2015. [abstract] [Open Access]

38. Particle radiation-induced non-targeted effects in bone marrow-derived endothelial progenitor cells
SP Sasi, D Park, S Muralidharan, J Wage, A Kiladjian, J Onufrak, H Enderling, X Yan, D Goukassian. Stem Cells Int., 2015:496512, 2015. [abstract] [Open Access]

37. Mathematical modeling of acupuncture as cancer symptom therapy: First steps
PA Johnstone, H Enderling. J. Acupuncture Meridian Stud., 8(3):113-4, 2015. [abstract] [Open Access]

36. Evolution and phenotypic selection of cancer stem cells
J Poleszczuk, P Hahnfeldt, H Enderling. PLoS Comp. Biol., 11(3):e1004025, 2015. [abstract] [Open Access]

35. Therapeutic implications from sensitivity analysis of tumor angiogenesis models
J Poleszczuk, P Hahnfeldt, H Enderling. PLoS One, 10(3):e0120007, 2015. [abstract] [Open Access]

34. Cancer stem cells: small subpopulation or evolving fraction?
H Enderling. Integr. Biol., 7(1): 14-23, 2015. [abstract] [Open Access]



33. Cardiovascular risks associated with low dose ionizing particle radiation
X Yan, SP Sasi, H Gee, J Lee, Y Yang, R Mehrzad, J Onufrak, J Song, H Enderling, A Agarwal, L Rahimi, J Morgan, PF Wilson, J Carrozza, K Walsh, R Kishore, DA Goukassian. PLoS One, 9(10):e110269, 2014. [abstract] [Open Access]

32. A multi-compartment mathematical model of cancer stem cell driven tumor growth dynamics
SL Weekes, B Barker, S Bober, K Cisneros, J Cline, A Thompson, L Hlatky, P Hahnfeldt, H Enderling. Bull. Math. Biol., 76(7):1762-82, 2014. [abstract] [Open Access]

31. TNF-TNFR2/p75 signaling inhibits early and increases delayed non-targeted effects in bone marrow-derived endothelial progenitor cells
SP Sasi, J Song, D Park, H Enderling, JT McDonald, H Gee, B Garrity, A Shtifman, X Yan, K Walsh, M Natarajan, R Kishore, DA Goukassian. J. Biol. Chem., 289(20):14178-93, 2014. [abstract] [Open Access]

30. Biphasic modulation of cancer stem cell driven solid tumor dynamics in response to reactivated replicative senescence
J Poleszczuk, P Hahnfeldt, H Enderling. Cell Prolif., 47(3):267-76, 2014. [abstract]

29. Therapeutic non-toxic doses of TNF induced remarkable regression in TNFR2-p75 knockdown Lewis lung carcinoma xenografts
SP Sasi, S Bae, J Song, A Perepletchikov, D Schneider, J Carrozza, X Yan, R Kishore,H Enderling, DA Goukassian. PLoS ONE, 9(3): e92373, 2014. [abstract] [Open Access]

28. Mathematical modeling of tumor growth and treatment
H Enderling, MAJ Chaplain. Curr. Pharm. Des., 20(30): 4934-40. [abstract]

27. TNF-α and IL-1α but not MCP-1 and Rantes increase significantly the formation of p-H2AX foci in naive BM-derived TNFR1/p55KO EPCs
SP Sasi, J Song, H Enderling, X Yan, DA Goukassian. J Radiat. Res. , 55: Suppl 1:i122-i123, 2014. [abstract] [Open Access]

26. A high-performance cellular automaton model of tumor growth with dynamcally growing domains
J Poleszczuk, H Enderling. Appl. Math., 5(1): 144-152, 2014. [abstract] [Open Access]


25. Unveiling stem cell kinetics: prime time for integrating experimental and computational models
H Enderling. Front. Oncol., 3:291, 2013. [abstract] [Open Access]

24. Simulating cancer: computational models in oncology
H Enderling, KA Rejniak. Frontiers. Oncol., 3:233, 2013. [abstract] [Open Access]

23. Formalizing an integrative, multidisciplinary cancer therapy discovery workflow
MF McGuire, H Enderling, DI Wallace, JS Batra, M Jordan, S Kumar, C Panetta, E Pasquier. Cancer Res., 73(20):6111-6117, 2013. [abstract] [Open Access]

22. Cancer stem cells: a minor cancer subpopulation that redefines global cancer features
H Enderling, L Hlatky, P Hahnfeldt. Front. Oncol., 3:76, 2013. [abstract] [Open Access]

21. Acute and fractionated irradiation differentially modulate glioma stem cell division kinetics
X Gao, JT McDonald, L Hlatky, H Enderling. Cancer Res., 73(5):1481-1490, 2013. [abstract] [Open Access]

20. Cancer stem cells and tumor dormancy
H Enderling. Adv. Exp. Med. Biol, 734:55-71, 2013. [abstract]
[Systems Biology of Tumor Dormancy Springer, 2013]

19. The tumor growth paradox and immune system-mediated selection for cancer stem cells
T Hillen, H Enderling, P Hahnfeldt. Bull. Math. Biol., 75(1):161-184, 2013. [abstract]


18. Immunoediting: Evidence of the multifaceted role of the immune system in self-metastatic tumor growth
H Enderling, L Hlatky, P Hahnfeldt. Theor. Biol. Med. Model., 9:31, 2012. [abstract] [Open Access]

17. Systems biology of tumor dormancy: linking biology and mathematics on multiple scales to improve cancer therapy
H Enderling, L Hlatky, P Hahnfeldt, N Almog. Cancer Res., 72(9):2172-2175, 2012. [abstract] [Open Access]

16. The promoting role of a tumor-secreted chemorepellent in self-metastatic tumor progression
H Enderling, L Hlatky, P Hahnfeldt. Math. Med. Biol., 29(1):21-29, 2012. [abstract]

15. Breaking the 'harmony' of TNF-α signaling for cancer treatment
SP Sasi, X Yan, H Enderling, D Park, HY Gilbert, C Curry, C Coleman, L Hlatky, G Qin, R Kishore, DA Goukassian. Oncogene, 31(37):4117-27, 2012. [abstract] [Open Access]


14. Non-Stem Cancer Cell Kinetics Modulate Solid Tumor Progression
CI Morton, L Hlatky, P Hahnfeldt, H Enderling. Theor. Biol. Med. Model, 8(1):48, 2011. [abstract] [Open Access]

13. Cancer stem cells in solid tumors: is 'evading apoptosis' a hallmark of cancer?
H Enderling, P Hahnfeldt. Progr. Biophys. Mol. Biol., 106(2), 391-399, 2011. [abstract]

12. Phenotypic transition maps of 3D breast acini obtained by imaging-guided agent-based modeling
J Tang, H Enderling, S Becker-Weimann, C Pham, A Polyzos, CY Che, SV Costes. Integr. Biol., 3(4):408-421, 2011. [abstract] [Open Access]


11. Quantitative modeling of tumor dynamics and radiotherapy
H Enderling, MAJ Chaplain, P Hahnfeldt. Acta Biotheor., 58(4), 341-353, 2010. [abstract]

10. Tumor morphological evolution: directed migration and gain and loss of the self-metastatic phenotype
H Enderling, L Hlatky, P Hahnfeldt. Biol. Direct, 5:23, 2010. [abstract] [Open Access]


9. Paradoxical dependencies of tumor dormancy and progression on basic cell kinetics
H Enderling, ARA Anderson, MAJ Chaplain, A Beheshti, L Hlatky, P Hahnfeldt.Cancer Res., 69(22), 8814-8821, 2009. [abstract] [Open Access]

8. Reply: Inflammatory breast carcinoma as a model of accelerated self-metastatic expansion by intra-vascular growth
H Enderling, L Hlatky, P Hahnfeldt. Br. J. Cancer, 101(6), 1030, 2009. [Open Access]

7. Migration rules: tumours are conglomerates of self-metastases
H Enderling, L Hlatky, P Hahnfeldt. Br. J. Cancer, 100(12), 1917-1925, 2009. [abstract] [Open Access] [JNCI editorial] [NCI Cancer bulletin]

6. The importance of spatial distribution of stemness and proliferation state in determining tumor radioresponse
H Enderling, D Park, L Hlatky, P Hahnfeldt. Math. Model. Nat. Phenom., 4(3), 117-133, 2009. [abstract] [Open Access]


5. Dependence of invadopodia function on collagen fiber spacing and crosslinking: computational modeling and experimental evidence
H Enderling, NR Alexander, E Clark, KM Branch, L Estrada, C Crooke, J Jourquin, N Lobdell, MH Zaman, SA Guelcher, ARA Anderson, AM Weaver. Biophys. J. 95(5), 2203-2218, 2008. [abstract] [Open Access]


4. A model of breast carcinogenesis and recurrence after radiotherapy
H Enderling, ARA Anderson, MAJ Chaplain. Proc. Appl. Math. Mech. 7(1), 1121701-2, 2007. [abstract]

3. A mathematical model of breast cancer development, local treatment and recurrence
H Enderling, MAJ Chaplain, ARA Anderson, JS Vaidya. J. Theor. Biol. 246(2), 2007. [abstract]


2. Visualisation of the numerical solution of partial differential equation systems in three space dimensions and its importance for mathematical models in biology
H Enderling, ARA Anderson, MAJ Chaplain, GW Rowe. Math. Biosci. Eng. 3(4), 571-582, 2006. [abstract]

1. Mathematical modelling of radiotherapy strategies for early breast cancer
H Enderling, ARA Anderson, MAJ Chaplain, AJ Munro, JS Vaidya. J. Theor. Biol.241(1), 158-171, 2006. [abstract]


Published Abstracts

12. H. pylori Infection Induces Early Expression of CD44 during the Progression of Gastric Cancer.
R Walker, Mejia J, H Enderling, Coppola D. Lab. Invest. 96(Suppl 1): 206A-206A, 2016

11. Proliferation saturation index predicts oropharyngeal squamous cell cancer gross tumor volume reduction to prospectively identify patients for adaptive radiation therapy.
Lewin T, Kim J, Latifi K, J Poleszczuk, Bull J, Byrne H, Torres-Roca J, Moros EG, Gatenby R, Harrison LB, Heukelom J, Mohamed ASR, Rosenthal DI, Fuller CD, Caudell JJ, H Enderling. Int. J. Radiat. Oncol. Biol. Phys. 94(4): 903, 2016

10. CD133 Protein expression as a biomarker for early detection of gastric cancer.
Diffalha SAL, R Walker, H Enderling, Coppola D, Pimiento J, Mejia J. Gastroenterology 150 (4): S874-S875, 2016

9. CD44, CD133 and Lgr5 as biomarkers for early detection of H. pylori-associated gastric cancer.
R Walker, Mejia J, H Enderling, Pimiento JM, Malafa M, Coppola D. The FASEB Journal 30 (1 Suppl): 696.4, 2016.

8. Personalizing the synergy of focal radiation and immunotherapy.
J Poleszczuk, Luddy K, Pilon-Thomas S, Schoenfeld JD, H Enderling. Cancer Res., 76 (14 Supplement): 4016, 2016

7. Cross-disciplinary methods for personalizing screening modalities for early gastric cancer intervention.
R Walker, Majia J, H Enderling, Pimiento JM, Coppola D. Cancer Res. 76 (14 Supplement): 1523, 2016

6. Systems biology approach predicts the diagnostic value of T effector : T regulatory cell ratio in clinical response to combined radiation/immunotherapy of high-risk soft tissue sarcoma.
S Prokopiou, J Poleszczuk, Robertson-Tessi M, Luddy KA, Fishman M, Moros E, Djeu JY, H Enderling. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. Philadelphia (PA): AACR; Cancer Immunol Res 3(10 Suppl):Abstract nr A19, 2015.

5. A systems biology approach to predict immunotherapy augmented abscopal effects.
J Poleszczuk, S Prokopiou, Robertson-Tessi M, Luddy KA, Moros E, Fishman M, Djeu JY, H Enderling. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. Philadelphia (PA): AACR; Cancer Immunol Res 3(10 Suppl):Abstract nr A18, 2015.

4. TNF-alpha and IL-1 alpha but not MCB-1 and Rantes increase significantly the formation of p-H2AX foci in naive BM-derived TNFR1/P55KO EPCs.
Sasi SP, Song J, Park D, H Enderling, Gee H, Garrity B, Shtifman A, Yan X, Walsh KA, Natarajan M, Kishore R, Goukassian D. J Radiat Res 55(Suppl 1): i122-3, 2014.

3. TNF-TNFR1/p55 or TNFR2/p75 Receptor-Ligand Interactions Inhibit Early and Increase Delayed Radio-Biological Bystander Responses in BM-Derived EPCs.
Muralidharan S, Sasi S, Yan X, H Enderling, Goukassian D. Circ Res 111(4) Supplement 184, 2012.

2. Increased cytokine and chemokine expression in U87MG glioblastoma cells after large clinically relevant single doses of ionizing radiation.
McDonald JT, Lee J, Rietman E, Lamont C, H Enderling, Peluso M, Hlatky L. Cancer Res 72(8), Supplement 1, 2012.

1. Cancer stem cells in solid tumors: Symmetric division, niche size, and invasive tumor morphology.
H Enderling, Hlatky L, Hahnfeldt P. Cancer Res 71(8), Supplement 1, 2011.


Book Chapters

6. Integrating experimental data to calibrate quantitative cancer models
H Enderling. doi:, BioRxiv, 2015.

5. Vectorization techniques for efficient agent-based model simulations of tumor growth
J Poleszczuk, H Enderling. doi:, BioRxiv, 2015.

4. Cancer stem cell kinetics

3. Cell-cell interactions in solid tumors: the role of cancer stem cells
X Gao, JT McDonald, L Hlatky, H Enderling. in: NEW CHALLENGES FOR CANCER SYSTEMS BIOMEDICINE (eds. d'Onofrio, Cerrai, and Gandolfi ), 2012.

2. Mathematical modelling of stem cells related to cancer
MJ Piotrowska, H Enderling, U an der Heiden, MC Mackey. in STEM CELLS AND CANCER (eds. T. Dittmar et al), 2008.

1. Mathematical Modelling of Breast Carcinogenesis, Treatment with Surgery and Radiotherapy, and Local Recurrence
H Enderling, JS Vaidya. in SELECTED TOPICS ON CANCER MODELLING GENESIS - EVOLUTION - IMMUNE COMPETITION - THERAPY (eds. N. Bellomo, M. Chaplain and E. De Angelis), Birkhäuser, 2008.